The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...